VIJAYA - Fundamental Analysis: Financial Health & Valuation

Last Updated Time : 19 Sept 25, 2:16 pm

Fundamental Rating: 4.0

📊 Core Financials Breakdown

Profitability

ROCE: 20.2% and ROE: 18.1% — strong indicators of efficient capital deployment and operational performance.

EPS: ₹14.1, with PAT rising from ₹33.9 Cr. to ₹38.4 Cr. — a solid 33.0% quarterly growth, reflecting healthy earnings momentum.

Debt-to-equity: 0.37 — moderate leverage, manageable for a service-based business.

Dividend Yield: 0.19% — minimal, suggesting reinvestment focus over income distribution.

Institutional Sentiment

FII holdings increased (+0.20%), DII holdings also rose (+0.35%) — positive institutional interest.

💰 Valuation Metrics

Metric Value Insight

P/E Ratio 73.9 Very high vs. industry average (41.3) — priced for aggressive growth.

P/B Ratio ~13.7 Elevated — reflects premium valuation for brand and scalability.

PEG Ratio 11.2 High — valuation stretched relative to earnings growth.

Intrinsic Value ~₹950–₹1,000 (est.) Current price of ₹1,045 is slightly above fair value.

🧠 Business Model & Competitive Edge

Core Operations: Vijaya Diagnostic Centre Ltd. operates an integrated diagnostic model offering pathology and radiology services across India.

Strengths

Strong brand presence in South India with expanding footprint.

Asset-light model with high operating margins.

ROE of 19% vs. industry average of 11% — superior capital efficiency

1

.

Retains 88% of profits — reinvestment-driven growth

1

.

Challenges

PEG ratio and valuation multiples suggest limited upside unless earnings accelerate.

RSI at 48.2 — neutral, MACD at 1.96 — mild bullish momentum.

📈 Entry Zone & Technicals

DMA 50: ₹1,043, DMA 200: ₹1,001 — price is hovering near both, indicating consolidation.

RSI: 48.2 — neutral zone.

MACD: 1.96 — bullish crossover.

📌 Entry Zone: ₹980–₹1,020 — ideal for accumulation on dips.

🕰️ Long-Term Holding Guidance

2025 Target: ₹1,150–₹1,250

2026–2028 Target: ₹1,400–₹1,600

2030 Target: ₹1,800+

Holding Strategy: Vijaya Diagnostic is a premium healthcare play with strong fundamentals, brand equity, and reinvestment-driven growth. Suitable for long-term investors seeking exposure to India’s expanding preventive healthcare and diagnostics market. Accumulate during technical weakness and hold through cycles.

You can explore Vijaya’s ROE and earnings analysis or review its live financial dashboard for deeper insights.

1

simplywall.st

Edit in a page